Scalper1 News
Rising biotech star Medivation started losing altitude in after-hours trading Thursday after its Q1 report missed estimates, in a day when several high-rated drug stocks reported. Medivation’s (MDVN) earnings excluding one-time items totaled 17 cents a share, reversing a year-earlier loss but missing analysts’ consensus by 10 cents, according to Thomson Reuters. Revenue climbed 48% to $129.2 million, about $20 million short of consensus. Scalper1 News
Scalper1 News